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ABSTRACT 
Morbidity in patients presenting with acute ST-segment elevation myocardial infarction 
remains significant despite prompt reperfusion by primary percutaneous coronary 
intervention. This has been partly attributed to “myocardial reperfusion injury” whereby the 
process of restoring coronary blood flow paradoxically induces myocardial injury and 
cardiomyocyte death, mitigating the full beneficial effects of reperfusion. A large number of 
cardioprotective therapies to reduce myocardial infarct size have been investigated in 
preclinical and small proof-of-concept clinical studies with mixed results. In this article, we 
provide an overview of the most promising cardioprotective therapies for reducing 
myocardial infarct size that warrant further investigation in outcome studies.  
Keywords: reperfusion injury, cardioprotection, ST-segment elevation myocardial 
infarction, myocardial infarct size 
 
INTRODUCTION  
Timely myocardial reperfusion through primary percutaneous coronary intervention (PPCI) 
or thrombolysis currently remains the most effective therapy to minimize myocardial infarct 
(MI) size and prevent heart failure in acute ST-segment elevation myocardial infarction 
(STEMI) patients. However, whilst rapid reperfusion therapy decreases immediate STEMI 
mortality, it paradoxically results in an increased incidence of long-term heart failure.1-3 
Myocardial reperfusion has been termed “a double-edge sword”4 due to the detrimental 
effects of acute ischaemia/reperfusion injury (IRI) on the heart. IRI results in 
cardiomyocyte death and may in fact contribute up to 50% of final MI size5. Four types of 
IRI have been recognised. So-called “myocardial stunning” and “reperfusion-induced 
arrhythmias” are reversible and self-limiting. The “coronary no-reflow phenomenon” and 
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“lethal myocardial reperfusion injury” are irreversible5 and have been the focus of 
significant research over the past 3-4 decades. Despite recent advances in minimizing 
ischaemic injury through the use of antithrombotic agents, anticoagulants, and stent 
delivery in the setting of PPCI, there is currently no established therapy for minimizing IRI. 
In this article we provide an overview of the most promising cardioprotective therapies for 
reducing MI size.  
BRIEF HISTORICAL PERSPECTIVE  
In 1986, Murry et al6 first showed that alternating left anterior descending (LAD) coronary 
artery occlusion and reflow followed by LAD occlusion for 90 minutes led to a 25% 
reduction in MI size in the canine heart6. This form of endogenous cardioprotection was 
termed ischemic preconditioning (IPC) and has been shown to be ubiquitous in several 
other organs and species7, 8. In 1993, Przyklenk et al9 found that transient intermittent 
occlusion and reperfusion in the circumflex coronary artery was able to reduce MI size by 
63% following LAD occlusion. This gave rise to the concept that cardioprotection could be 
induced by applying cycles of brief ischaemia and reperfusion to an organ or tissue remote 
from the heart in an intervention termed “remote ischemic conditioning” (RIC). It was not 
until 2003 that Zhao et al10 discovered that applying three cycles of 30-seconds LAD 
coronary artery occlusion and reflow at the onset of myocardial reperfusion could reduce 
MI size by 44% in the canine heart.  This phenomenon was termed ‘ischaemic 
postconditioning’ (IPost)8 and is  relevant in the context of a STEMI, where the overall 
ischaemic insult cannot be predicted. 
 
OVERVIEW OF MECHANISTIC PATHWAYS 
The mechanisms involved in cardioprotection are complex and not yet fully understood 
(comprehensively reviewed in7, 8, 11, 12). A simplistic representation classifies the signal 
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transduction into three levels: triggers (adenosine, bradykinin and opioids), intracellular 
mediators (protein kinases) and effectors (mitochondria, cytoskeleton). Three parallel 
pathways are currently understood to be involved: the Reperfusion Injury Salvage Kinase 
(RISK), the Survivor Activator Enhancement (SAFE) pathway, and an unnamed third 
pathway involving G-protein-coupled or natriuretic-peptide receptors, nitric oxide synthase, 
nitric oxide and protein kinase G. The underlying mechanism linking remote organs and 
the heart in RIC remains unknown. It has been postulated that this link may involve the 
release of local autocoids, which stimulate the sensory afferent neural pathway remotely, 
leading to the production of blood-borne cardioprotective factors (nitric oxide, MicroRNA-
144, Stromal derived factor-1α) (comprehensively reviewed in13). The first window of 
protection from the conditioning stimulus occurs immediately and lasts for 2-3 hours, and 
the second one termed the second window of protection (SWOP) appears 12-24 hours 
later, and lasts up to 72 hours. Repeated RIC post-MI has also been shown to prevent left 
ventricular (LV) remodelling via exosome-mediated intercellular communication14. 
Increased understanding of IRI pathophysiology has helped to identify potential 
therapeutic targets as illustrated in Figure 1. 
The mechanistic insights underlying ischaemic conditioning have enabled the 
development of pharmacological agents to mimic cardioprotection5, 15. A number of these 
including atrial natriuretic peptide (ANP)16, exenatide17, metoprolol18 and adenosine19-21 
have shown promise in the clinical setting. Others, such as glucose-insulin-potassium22 23, 
cyclosporine 24, 25 and erythropoietin26-28 have failed to show consistent results (reviewed in 
29). 
 
THERAPEUTIC INTERVENTIONS SHOWING PROMISE IN THE CLINICAL SETTING 
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A number of proof-of-concept studies have shown promising results in the clinical setting 
and some of these major studies are summarized in Table 1. In the next few paragraphs 
we will elaborate on the promising therapeutic interventions to date. 
 
IPost 
IPost was first implemented in a clinical trial in 2003 - only 2 years following its discovery. 
Whilst numerous clinical studies have investigated the benefit of IPost in STEMI and have 
produced promising results30-32, other studies have been either neutral33, 34 or shown the 
potential for clinical harm 35 36. IPost may not benefit all patients and its clinical application 
is limited by its invasive nature and a minor risk of distal microembolisation35, 37, 38. A meta-
analysis38 of 10 trials (total of 560 patients) suggested that IPost may confer 
cardioprotection in terms of relatively reduced cardiac enzyme levels and increased LV 
function and that these effects were more pronounced among young male patients who 
had direct stenting. The DANAMI-3 trial39 has completed recruitment of 2000 patients into 
3 arms: conventional treatment, IPost or deferred stenting. It will hopefully provide some 
definite answers on whether these strategies can improve clinical outcomes at 2 years 
post PPCI. (Table 2) 
 
Remote ischemic postconditioning (RIPost) 
Several proof-of-concept studies have shown that intermittent inflation and deflation of a 
cuff around a limb during a STEMI leads to a reduction in infarct size40-44 not only in 
patients undergoing PPCI but also in those undergoing thrombolysis44. The initial cohort 
study from Botker et al41 was followed-up for a median of 3.8 years and fewer adverse 
events were observed in the RIPost group45. Whether RIPost can also reduce cardiac 
death and hospitalisation for heart failure at 1 year in PPCI patients is currently being 
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investigated in a joint international multicentre randomised controlled trial of 4200 patients 
(ERIC-PPCI and CONDI2 trials - ClinicalTrials.gov Identifier: NCT02342522 and 
NCT01857414) 46. (Table 2) 
 
Metoprolol 
Early use of metoprolol has been shown to increase myocardial salvage in a porcine 
model of acute MI47. In the clinical setting, Ibanez et al18 showed a 20% reduction in infarct 
size assessed by cardiac magnetic resonance (CMR) and LV ejection fraction (LVEF) in 
response to intravenous metoprolol. The pharmacological intervention was administered 
before reperfusion in anterior STEMI patients with Killip class II or less presenting within 6 
hours of onset of symptoms. This benefit persisted at 6 months as demonstrated by an 
improvement in LVEF48. The EARLY BAMI study49 is currently investigating early 
metoprolol use during ambulance transfer and will be recruiting patients within 12 hours of 
symptoms onset. The primary endpoint will be infarct size as measured by CMR at 30 
days and it is expected to enroll 408 patients. (Table 2) 
 
Exenatide 
Glucagon-like peptide 1 and its analogue exenatide have been shown to reduce MI size in 
animal studies50 51. Lonborg et al17 demonstrated in 172 STEMI patients that exenatide 
administered as an infusion 15 minutes prior to reperfusion and continued for 6 hours 
increased myocardial salvage. In particular, there was a 30% reduction in MI size in those 
presenting within 132 minutes52. Woo et al53 also showed a significant impact on infarct 
size reduction with subcutaneous exenatide in a smaller cohort of patients. Therefore 
there is a pressing need to perform a large randomized controlled trial to investigate 
whether exenatide use in STEMI also leads to an improvement in clinical outcomes. 
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Atrial Natriuretic Peptide  
Yang et al 54 demonstrated in a rabbit model, that ANP administered just prior to 
reperfusion limited MI size. The cardioprotective benefit of ANP was confirmed in the J-
WIND trial16. This was a trial of 569 STEMI patients that showed a 15% reduction in 
enzymatic MI size and subsequent improvement in LVEF and reduction hospitalisation for 
heart failure and death at 6 months in the arm receiving ANP. However, this study was not 
powered for clinical outcomes and these findings need to be confirmed in larger, 
adequately powered studies.  
 
Adenosine 
Adenosine has been extensively investigated as a cardioprotective agent in both 
experimental and clinical studies. In the pre-clinical setting it is generally accepted that the 
administration of adenosine prior to experimental IRI can reduce MI size55. Whether 
adenosine is cardioprotective when it is given at the time of reperfusion to target IRI has 
been unclear in experimental studies56, 57. A number of clinical studies have investigated 
the effect of adenosine when administered as an adjunct to reperfusion in STEMI patients. 
Many of these studies have reported beneficial effects in terms of preventing the coronary 
no-reflow phenomenon. Duration of symptoms may be important in explaining these 
experimental discrepancies. Intra-coronary adenosine has been reported to be more 
effective in limiting infarct size in patients receiving reperfusion within 3 hours of symptoms 
onset19, 58, 59. A recent meta-analysis60 showed that intracoronary adenosine was 
associated with less heart failure in 8 randomized controlled trials however there was no 
difference in mortality and as such, this avenue warrants further investigation. The 
REFLO-STEMI trial is currently investigating the role of intra-coronary adenosine on MI 
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size measurement using CMR, and has been designed to address the flaws of previous 
studies.61  
 
Combination therapy 
Another approach would be to use combination therapy targeting multiple cardioprotective 
pathways in order to minimise IRI. Following the promising pilot studies with exenatide and 
RIPost in STEMI, Alburquerque-Béjar et al62 showed an additive benefit in infarct size 
reduction through a combination of these 2 interventions in a porcine model. The 
COMBAT-MI study (ClinicalTrials.gov Identifier: NCT02404376) will be investigating the 
potential additive benefit of infarct size reduction in the clinical setting. The combination of 
RIPost and IPost has also been recently studied in a large study of 696 STEMI patients 
and showed better myocardial salvage in patients receiving RIPost in combination with 
IPost63.  
 
PROMISING CARDIOPROTECTIVE THERAPIES FAILING TO SHOW A BENEFIT IN 
THE CLINICAL SETTTING 
Disappointingly, over the past 2 years there have been a number of studies reporting 
neutral results in several otherwise promising cardioprotective strategies. Cooling to <35°C 
has been shown to reduce MI size both in animal models64, 65 and in an initial pilot study66. 
However, the CHILL-AMI study67 (120 patients) failed to show an improvement in MI size 
despite achieving a temperature of <35°C prior to reperfusion by cold saline and 
endovascular cooling. The recently published VELOCITY study by Nichol et al68 
randomized 53 patients to peritoneal hypothermia versus control and found no benefit in 
infarct size reduction. Pre-clinical data has shown impressive cardioprotective benefit of 
sodium nitrite in the context of STEMI69-71. However, Siddiqi et al72 and Jones et al73 both 
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failed to show a reduction in infarct size via the intravenous and intracoronary route 
respectively. The NOMI study was reported at the European Society of Cardiology 
conference in 2014 and demonstrated that inhaled nitrous oxide did not reduce infarct size 
when compared to placebo74. Recent phase II trials investigating Delcasertib (delta-protein 
kinase C) in the PROTECTION-AMI study75, TRO40303 (inhibitor of the mitochondrial 
permeability transition pore) in the MITOCARE study76 and Bendavia (a mitochondria-
targeting peptide) in the EMBRACE-STEMI study77 as well as a trial investigating 
mangafodipir78 (manganese dipyridoxyl diphosphate) all proved to be safe but failed to 
translate to a reduction in infarct size in STEMI patients when administered prior to 
reperfusion. The long awaited large randomized CIRCUS trial79 comprising of 975 STEMI 
patients did not show a benefit in the combined primary endpoint (adverse LV remodelling, 
heart failure and all cause death). This failure may have been related to a novel 
formulation of cyclosporine (Ciclomulsion) used in the study which may have interfered 
with its cardioprotective benefit.80 The failure to translate the cardioprotective benefits of 
these promising agents has been attributed to a number of factors such as the use of 
inappropriate animal models, poorly designed clinical trials, interaction of comorbidies, and 
polypharmacy.81 In the next paragraph, we will explore the various factors we need to take 
into account when designing clinical studies in this field.  
HOW TO OPTIMISE THE TRANSLATION OF CARDIOPROTECTION 
The failure to translate cardioprotective therapies proven to reduce infarct size in animal 
models into patient benefit has been the subject of several recent articles82-85.  There are 
certain factors that need to be taken into account whilst designing clinical studies in order 
to improve the chances of reaping their maximum benefit in the clinical environment. In the 
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setting of STEMI patients undergoing PPCI, these keys points need to be taken into 
account: 
 Patients that are most likely to benefit from the cardioprotective therapy should be 
recruited: large area at risk (>30% of the LV)34; no coronary collateralisation 
(Rentrop<1); occluded artery prior to PPCI (TIMI 0 or 1); those presenting within 2-3 
hours of symptoms onset19 52. 
 Only therapies having shown conclusive cardioprotection in pre-clinical studies 
should be tested. 
 Therapy should be administered prior to myocardial reperfusion via PPCI. 
 Confounding factors such as age, pre-infarct angina, diabetes mellitus, 
hypertension, dyslipidaemia and concomitant medications (nitrates, morphine, 
nicorandil, sulphonamides), which can interfere with cardioprotection, should be 
taken into consideration. 86 
 Relevant clinical endpoints for assessing cardioprotective efficacy should be 
selected. These include: MI size (enzymatic or CMR); myocardial salvage index 
(more sensitive than MI size reduction); microvascular obstruction; LV remodelling 
(LVH, LVEF and indexed LVEDV or LVESV); cardiac death; hospitalisation for heart 
failure. 
Implementing the above steps should provide an optimal clinical platform to test therapies 
with promising preclinical results. 
 
CONCLUSION 
The field of clinical cardioprotection has a chequered history with a disappointingly large 
number of neutral studies in which novel cardioprotective therapies have failed to improve 
clinical outcomes. However numerous promising therapeutic interventions are available for 
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exploration, and larger trials examining outcomes are ongoing.  Future studies need to be 
carefully designed by taking into account lessons learnt from recent studies. As such, 
minimising IRI may still be achievable in certain specific circumstances. 
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Figure 1: Schematic representation of the main pro-survival signalling pathways and the potential sites of actions for novel therapies 
recently investigated in the setting of STEMI to minimize IRI. 
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Table 1: Major promising clinical in STEMI patients 
Clinical study Therapeutic intervention 
 
Number Outcome Comments 
Pharmacological agents 
Kitakaze et al 
200760 
J-WIND 
 72 hours IV carperitide (atrial 
natriuretic peptide analogue) 
infusion started prior to PPCI 
569 
 
15% reduction in 72 hours AUC total CK  
2.0% absolute increase in LVEF 
Atrial natriuretic peptide targets pro-survival 
kinase pathways such as the cGMP and RISK 
pathways 
Lonborg et al 
201262  
IV infusion of exenatide started 15 
minutes prior to PPCI and 
continued for 6 hr 
 
107  
 
Increase in myocardial salvage index (0.62 to 0.71) 
23% reduction in MI size at 3 months on CMR 
Patients presenting with short ischaemic times (≤132 
minutes) had greater myocardial salvage88  
Exenatide, a GLP-1 analogue, targets pro-
survival kinase pathways such as the RISK 
pathway 
Ibanez et al 
201363 
IV metoprolol (3x5mg) in 
ambulance prior to PPCI 
270 Reduction in MI size by CMR at one week. Increased LVEF 
at 6 months 
Improvement in clinical outcome at 2 years 
Reduced: incidence of severely depressed LVEF (<35%) at 
6 months by 60%; less need for ICD by 65% at 6 months 
and reduced HF at 2 years 89 
The mechanism of cardioprotection is not 
currently clear 
Remote ischaemic perconditioning 
Botker et al 
201054  
Four x 5-minutes upper arm cuff 
inflations/deflations in the 
ambulance prior to PPCI 
142 
 
Increase in myocardial salvage index at 30 days 
No difference in MI size (SPECT or peak Troponin) 
 
First study to test effect of RIC in PPCI-treated 
STEMI patients. Reduced MI size in LAD 
STEMI. 
Rentoukas et al 
201055  
Three x 4-minutes cuff 
inflations/deflations at the hospital 
prior to PPCI 
93  
 
Better ST resolution and lower peak Troponin I. Synergistic 
effects with morphine. 
 
 
Crimi et al 
201357 
Three x 5-minutes thigh cuff 
inflations/ deflations at onset of 
reperfusion by PPCI 
100  
LAD  
only 
20% reduction in 72 hours AUC CK-MB.  
% reduction in myocardial oedema by CMR 
 
First study to show effect of RIC given at onset 
of reperfusion via PPCI. Also, first study to report 
effect of RIC on enzymatic MI size and 
myocardial oedema. 
White et al 
201456 
Four x 5-minutes upper arm cuff 
inflations/deflations at the hospital 
prior to PPCI 
197 27% reduction in MI size by CMR 
19% reduction in myocardial oedema by CMR 
 
First study to show effect of RIC given prior to 
PPCI on MI size and myocardial oedema by 
CMR 
Yellon et al 
2015 
ERIC-LYSIS44  
 
Four x 5-minutes upper arm cuff 
inflations/deflations at hospital 
prior to thrombolysis for STEMI 
519 17% reduction in enzymatic MI size (CK-MB and Trop-T) 
 
Only study to test effect of RIC in thrombolysed 
STEMI patients 
Sloth et al 
201486 
 
Four x 5-minutes upper arm cuff 
inflations/deflations in the 
ambulance prior to PPCI 
251 51% reduction in all-cause mortality, nonfatal MI, TIA or 
stroke, HHF at 3.8 years 
First study to test effect of RIC on long-term 
outcomes following PPCI 
 
STEMI: ST-segment elevation myocardial infarction; IV: intravenous; AUC: area under curve; CK: creatine kinase; LVEF: left ventricular ejection fraction; cGMP: cyclic guanosine monophosphate; RISK: 
reperfusion injury salvage kinase; MI: myocardial infarct; CMR: cardiovascular magnetic resonance imaging; LVESV: left ventricular end-systolic volume; GLP-1: glucagon-like peptide-1; AAR: area at risk; 
HF: heart failure 
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Table 2: Ongoing clinical studies  
  
Clinical study Treatment protocol 
 
Number of 
patients 
Outcome Comments 
Ongoing studies on clinical outcomes 
 
Engstrom et al  
DANAMI-339 
 
Four x 30-seconds 
angioplasty balloon 
inflations/deflations during 
PPCI 
2000 
Completed 
recruitment 
All-cause mortality, heart failure at 2 years 
Results awaited 
First study which will report effects of IPost on 
long-term clinical outcomes 
Botker  
CONDI-2 (NCT02342522) 
Hausenloy 
ERIC-PPCI (NCT01857414) 
Four x 5-minutes upper arm 
cuff inflations/deflations prior 
to PPCI 
 
4300 
Ongoing  
Primary endpoint of cardiac death and HHF 
at 12 months 
Collaboration between UK, Denmark.  
First study to test effect of RIC on long-term 
clinical outcomes at primary endpoint following 
PPCI 
Ongoing phase II studies 
Nazir et al61 
REFLO-STEMI 
Intracoronary adenosine or 
sodium nitroprusside versus 
placebo during PPCI 
240 patients 
Completed 
recruitment 
Primary endpoint of infarct size by CMR at 
48-72 hours post PPCI 
3-arm study in 4 UK centres which also look at 
MVO by CMR as a secondary endpoint. 
Roovlink et al49 EARLY BAMI Intravenous metoprolol starting 
as soon as possible after the 
diagnosis of STEMI 
408 patients 
Ongoing 
Primary endpoint of infarct size by CMR at 
30 days 
Multicentre study looking to start metoprolol in 
the ambulance and including patients with up 
to 12 hours of symptoms duration as 
compared to the recent study by Ibanez et al47 
Halladin et al87  
IMPACT  
Intracoronary and systemic 
administration of melatonin 
during PPCI 
40 patients Primary endpoint of myocardial salvage by 
CMR on day 3-5 post PPCI 
First pilot study to investigate the 
cardioprotective benefit of melatonin in STEMI 
patients 
Ishihara et al 88 Intravenous TY-51924 prior to 
PPCI 
100 patients Primary endpoint of myocardial salvage by 
SPECT 
TY-51924 is the latest sodium/hydrogen 
exchanger designed to improve its safety 
profile and this is the first study in STEMI to 
assess its efficacy and safety 
Bulluck/ Fröhlich et al89 
MINIMISE STEMI 
Intravenous spironolactone 
prior to reperfusion by PPCI 
followed by 3 months oral 
therapy 
150  
Ongoing 
Primary endpoint of infarct size by CMR at 3 
months 
First clinical study to investigate the role of 
spironolactone to minimise reperfusion injury 
IPost: Ischaemic postconditioning; RIC: remote ischaemic conditioning; STEMI: ST-segment elevation myocardial infarction; AUC: area under curve; CK: creatine kinase; PPCI: primary percutaneous 
coronary intervention; CK-MB: creatine kinase MB isoenzyme; SPECT: single-photon emission computed tomography; LVEF: left ventricular ejection fraction; PPCI: primary percutaneous coronary 
intervention; MI: myocardial infarct; LAD: left anterior descending artery; CMR: cardiovascular magnetic resonance imaging; Trop I: Troponin I; TIA: transient ischaemic attack; HHF: hospitalisation for heart 
failure; 
 
